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The purpose of this thesis is to examine familial hypercholesterolemia (FH) and emerging 
pharmacogenomics therapies that propose to lower serum low density lipid (LDL) levels. The 
search of various data bases resulted in nine research articles being selected for review. 
Syntheses of the articles suggest emerging phamacogenomic drug therapy can improve treatment 
outcomes for individuals with a diagnosis of FH. The Human Genome Project (HGP) has had far 
reaching applications for genomic technologies and pharmacagenomic interventions, tailored to 
human conditions associated with select genomic traits. Synthesis of nine research articles 
demonstrate that little is known on the topic and reveals extensive gaps in the evidence. This 
thesis concludes with implications for nursing education, practice, policy and research along with 
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 The Human Genome Project (HGP), completed in 2003, involved an international cadre 
of researchers who mapped the sequence of all human genes to develop the genome of the 
species Homo sapiens. Metaphorically, sequencing of the human genome provides a textbook 
with pages for each gene describing the makeup of the human body. This knowledge has led to 
the discovery of more than 1,800 disease genes such as Familial hypercholesteremic (FH) 
(National Institute of Health, 2015). An outcome of the HGP has assisted researchers in 
identifying a particular gene suspected of causing a specific inherited disease in a matter of days, 
rather than years. Since the HGP was completed more than 2,000 genetic tests have been 
developed to identify various human conditions. Another outcome of the HGP resulted in 
improved genetic testing which allows for specific identification of gene mutations within a 
strand of deoxyribonucleic acid (DNA) that could determine if a person or family is at genetic 
risk for developing a particular condition. Likewise, DNA screening can assist the healthcare 
provider in diagnosing diseases with greater accuracy and then personalizes medical and 
pharmacological intervention to treat the genetically based condition (National Institute of 
Health, 2015).   
Excessive serum cholesterol (hypercholesterolemia) in the body greatly increases an 
individual’s risk of developing cardiac and other vascular related diseases. Familial 
hypercholesterolemia (FH), a rare genetic condition, is associated with an excessive and 
persistent accumulation of cholesterol in the blood. It is estimated that one in every 500 
individuals has the genetic propensity for developing FH evidenced by high serum cholesterol 
levels (National Human Genome Research Institute, 2015). There are two types of cholesterol 




that people are most familiar with, high density lipoprotein (HDL) and low density lipoprotein 
(LDL). Sometimes referred to as "good cholesterol” the HDL ‘picks up’ excess cholesterol in the 
blood and disperses it to the liver where it is then broken down. A high level of LDL or ‘bad 
cholesterol’ over time accumulates in blood vessel wall linings (plaques) throughout the body 
which results in narrowing of vessel. Eventually, plaques can block blood flow which increases 
the risk of developing coronary artery disease, vascular disease and stroke.  
Serum cholesterol level is measured in milligrams (mg) of cholesterol per deciliter (dL) 
of blood or mill moles (mmol) per liter (L). Regarding the targeted serum level of HDL, the goal 
should be having a higher number, while for LDL the goal should be for a lower number. One 
diagnostic measure for FH is having a persistent serum LDL level above >190mg/dL (National 
Library of Medicine, 2015). A treatment goal for individuals with FH is to maintain a serum 
LDL level of <190mg/dL (High cholesterol, 2015; Learning about familial hypercholesterolemia, 
2015) (See Table 1.). The HGP along with facilitating quicker diagnoses, led to development of 
new classifications of drugs to treat genetically based FH (pharmacogenomics) that tailor 
treatment approaches for an individual (precision medicine). Ultimately, precision medicine can 
improve treatment outcomes and reduce long term comorbidities, in this case FH which is the 
focus of this thesis. 
Problem Statement 
 The purpose of this integrative review was to examine the effects of pharmacogenomics 
in managing or reducing serum cholesterol levels in individuals who have been diagnosed with 
FH.  





 Recently genomics, pharmacogenomics and precision medicine received extensive media 
attention at the national level. In his 2016 State of the Union Address, President Obama launched 
a $215 million Precision Medicine Initiative in the 2016 Federal Budget. His initiative focuses 
on research and data-sharing among researchers and clinicians to advance an agenda of precision 
medicine and its effects on treatment and outcomes (Williams et al., 2016). In respect to nursing 
education, the American Nurses Association along with other specialty nursing organizations 
recommend that curricula include content on genetics to enhance genomic nursing competencies 
in graduates (Cheek, Bashore, & Brazeau, 2015; Greco, Tinley, & Seibert, 2011; Howington, 
Riddlesperger, Cheek, 2011). Given these two nationally focused imperatives, this integrative 
review will focus on pharmacogenomic therapy outcomes in individuals with a diagnosis of FH.  
Table 1. Diagnostic Parameters for Serum Cholesterol Levels. 
HDL 
LDL Familial Hypercholesterolemia 
Normal: 60 mg/dL or 
above 
 
At Risk: 40 mg/dL or 
below 




At Risk: More than 
130mg/dL 
LDL: > 190 mg/dL or more 
 
 
HDL: < 60 mg/dL 
Note. Adapted from “High Cholesterol,” by Mayo Clinic, 2016, http://www.mayoclinic.org/diseases-
conditions/high-blood-cholesterol/in-depth/hdl-cholesterol/ART-20046388 
Background 
Treatment of choice for managing hypercholesterolemia historically comprised lifestyle 
behavior modifications and administration of HMG-CoA reductase inhibitors (i.e., statins). 




However, in individuals diagnosed with FH, lifestyle changes coupled with statin drug therapy 
generally is ineffective in lowering serum cholesterol, in particular LDL, to recommend target 
levels (Kolovou, Vasiliadis, Gontoras, Kolovou, & Hatzigeorgiou, 2015). Satin drugs can have a 
high degree of variability in lowering LDL especially in individuals with FH associated with 
genetic factors that impact drug responsiveness. For individuals who are resistant to traditional 
interventions to manage hypercholesterolemia, genetic screening could be the next step in the 
treatment care plan.   
Genetic Screening 
Genetic screening may be recommended for individuals who persistently maintain a high 
serum LDL even with lifestyle modifications (dietary; physical activity) along with statin 
medication regimen (Thomas, 2014).  An individual can have the genetic traits for heterozygous, 
homozygous or polygenic FH. All three of these genetic mutations are associated with an 
increased serum LDL that is deposited throughout the body which pose risks for developing 
coronary heart and other vascular diseases.  Other physical manifestations of FH include 
xanthomas in the eyes, tendons, elbows, hands and knees. Average life expectancy in the US of 
persons with FH is estimated to be in the early twenties if left untreated compared with a life 
expectancy of 78.7 years of an individual who does not have the condition (Thomas, 2014). 
Individuals having the heterozygous (HeFH) genetic trait have either one mutation in a 
single gene or multiple mutations in different genes. They are at significant risk for a premature 
heart attack which is 20 times higher than the general population. Coronary complications are 
more likely to occur in males with this genetic trait (50%) before 50 years of age and in females 
(30%) before 60 years of age (Sniderman, Tsimik & Fazio, 2014).  




Individuals with the homozygous (HoFH) genetic trait have two mutated copies of the 
same gene that causes a specific type of FH.  Individuals with this genetic trait are at even 
greater risk of developing CHD and other elevated serum LDL level associated complications. 
For example, with HoFH acute coronary attacks and cardiac disease can occur in an individual 
even before the end of the second decade of life (Sniderman, Tsimikas & Fazio, 2014).   
The polygenic genetic phenotype of FH, involves a combination of any of 12 different 
single nucleotide polymorphisms in select genes that are believed to be associated with FH. 
Precise epidemiological and bio statistical information on this genotype was not available in the 
literature (Sniderman, Tsimikas & Fazio, 2014). 
Genomics and Emerging Pharmacogenomic Interventions 
The HGP identified three specific genetic traits that lead to developing FH, specifically 
the Low Density Lipoprotein Receptor Gene (LDLR), the Proprotein Convertase Substilin/Kexin 
9 gene (PCSK9), and the Apolipoprotein B (APOB) gene. Each of these genetic traits will be 
discussed in the next few paragraphs (Sniderman, Tsimikas & Fazio, 2014).  
The LDLR gene, most commonly associated with FH, is responsible for construction of 
LDL receptors throughout the body and thereby removing LDL from the blood. This particular 
gene is integral to controlling serum LDL levels. In turn, an insufficient amount of LDL 
receptors impairs LDL absorption resulting in high level of LDL circulating in the blood 
resulting in hypocholesteremia (Sniderman, Tsimikas & Fazio, 2014). . 
The PCSK9 gene controls the circulating amount of the PCSK9 protein which regulates 
the number of LDL receptors that adhere to the surfaces of cells. Mutations in the PCSK9 gene 
can lead to either an increase or decrease in activity of the protein regulators. An increase in 
activity will lead to an increase in the breakdown of LDL receptors throughout the body; thus, 




circulating LDL is not being absorbed by LDL receptors, resulting in hypercholesterolemia. 
Decreasing the activity of the PCSK9 protein can result in less destruction of LDL receptors; 
thereby lowering the circulating level of LDL (Sniderman, Tsimikas & Fazio, 2014).  
The APOB gene encodes for the APOB protein which transports cholesterol throughout 
the body and allows the lipoprotein to attach to LDL receptors for absorption. When the gene 
mutates the APOB protein does not form correctly and impedes the LDL receptor from binding  
and absorbing LDL, resulting in hypocholesteremia (Sniderman, Tsimikas & Fazio, 2014).  
Therapeutic Management of FH 
First line treatment for FH includes the management of cholesterol through lifestyle 
modification such as limiting animal fat intake to less than 30% of total calories. This can be 
accomplished by reducing or eliminating animal fats such as pork, beef and dairy products. 
Another lifestyle modification focuses on increasing physical activity which in some cases also 
lowers serum LDL cholesterol. If lifestyle modification are not effective pharmacological 
therapies may be started, the most common being statin drugs. Statins generally are effective for 
lowering serum LDL levels in most individuals; however, those with FH often demonstrate 
lower or no less therapeutic response to statins (National Human Genome Research Institute, 
2015). Recent genetically based FH pharmacologic interventions can personalize treatment 
options to manage hypercholesterolemia based on genetic traits such as PCSK9 inhibitors, 
APOB inhibitors and MTP inhibitors (Sniderman, Tsimikas & Fazio, 2014) (See Table 2). 






Table 2. Genetic Trait, Pharmacogenetics Therapies and Actions. 
Gene Trait  Pharmacogenetics Therapies Action 
Proprotein Convertase 
Substilin/Kexin 9 
alirocumab (Praluent),  
evolocumab (Repatha) 
Monoclonal antibodies 
that destroys the PCSK9 
protein. 
Apoliprotien B mipomersen sodium(Kynamro) Inhibits synthesis of 
APOB protein in the liver 
Microsomal Triglyceride 
Transfer Protein 
lomitapide (Juxtapid) Inhibits MTP which is 
essential in the formation 
of very low density lipids 
Note. Adapted from “The Severe Hypercholesterolemia Phenotype.” by Sniderman, A. D., Tsimikas, S., & Fazio, S, 
2014, Journal of the American College of Cardiology, 63(19), 1935-1947. 
Methods 
 This thesis presents an integrative review of literature that focused on pharmacologic and 
lifestyle management of hyperlipidemia in FH. Key terms used in the literature search included: 
“pharmacogenomics,” “pharmacogenetics,” “genetics,” “familial hypercholesterolemia,” 
“dyslipidemia,” “genetic screening,” “PCSK9,” “APOB,” “MTP inhibitors,” “statins.” Databases 
for the search included CINAHL, Medline, PubMed and Cochrane. Inclusion criteria were peer-
reviewed research articles published from 2009 to 2015, and written in the English language. 
Each article was individually evaluated for relevance to the topic and application to FH therapy. 
A table that summarizes findings from each was developed and is included in the appendices 




(see appendix B).  Subsequently all of the critiques were synthesized by the researcher and key 
data were extracted. Consistent and inconsistent findings were noted along with gaps in the 
literature. Recommendations for future research were identified. Implications for nursing 
practice, policy and education are included along with limitations of this review. 
Eight studies were included in the final analysis and an additional nine articles gave 
further relevance to this review. Primary searches contained the search terms 
“pharmacogenomics” or “pharmacogenetics” which yielded N=18,312 studies. Once the topic of 
FH was chosen subsequent searches contained the search term “familial hypercholesterolemia” 
and included a specific type of pharmacogenomic therapy (“PCSK9,” “APOB,” “MTP” and 
“inhibitor”) associated with FH. Each search included the drug class and FH, and an additional 
limiting factor was the inclusion of statins as a comparison drug, and eight studies met inclusion 
criteria (see appendix A). Seven of the studies where randomized, double-blind, placebo-
controlled experiments; one was a case-study; seven studies used humans as study subjects; and, 
one used mice. Of these, three studies examined the use of Evolocumab, a PCSK9 inhibitor as 
potential genetically targeted drug therapy for individuals with FH; another two studies 
examined Mipomersen an Apoliprotein B protein inhibitor; and, three other studies examined 
Lomitapide an MTP inhibitor. In addition to the eight studies, searches that yielded articles that 
did not include original findings but were useful in giving background information were included 
(n=9) along with other pertinent and relevant sources such as webpages (n=4).  
Results 
 This next section highlights each pharamacogenomic therapy in depth using data from 
drug trials, case-studies and experiments. Results and limitations are noted in each subheading. 




Following this is a discussion of the results and the implications of these therapies on individuals 
with FH. 
PCSK9 Inhibitors 
 The literature indicated that PCSK9 is not involved in the synthesis of cholesterol. For 
this reason statins tend to be ineffective in individuals with PCSK9 induced FH thus creating the 
need for another type of intervention. Statins are correlated with a direct increase in PCSK9 
levels in individuals with PCSK9 induced FH. Consequently, statin drugs not only are ineffective 
but not beneficial in reducing the etiological agent of this classification of FH (Faiz, Hooper, & 
Bockxmeer, 2012).  
In a study of the PCSK9 inhibitor alirocumab, (i.e. ODYSSEY COMBO I Study) 
(N=316) patients at high cardiovascular risk were administered a PCSK9 inhibitor with a statin 
medication of which they were at the maximally tolerated dose. In a multicenter study located in 
76 sites across the US, data were collected for a phase 3, randomized, double-blind 52 week trial 
study to observe the effectiveness of alirocumab. Participating subjects over 18 years of age, 
with an established diagnoses of coronary heart disease, persistent hypercholesterolemia having 
either as serum LDL>70 with coronary artery disease (CAD); or, serum  LDL>100 and CAD 
risk equivalents (e.g. diabetes, hypertension, kidney disease, obesity). The study findings 
indicated that the PCSK9/Statin combo lowered LDL 48% from baseline compared to the serum 
LDL level in subjects receiving only a statin drug. After 24 weeks of administration of a PCSK9 
75mg every 2 weeks lead to a mean LDL of 51 mg/dl vs statin alone (98 mg/dl) in patients with 
hypercholesterolemia despite maximally tolerated statin therapy (Kereiakes et al., 2015). 
Combination of alirocumab in adjunct to a statin reduced LDL from baseline by 48.2% where as 
placebo and statin therapy reduced LDL by 2.3% by week 24. This equated to a mean difference 




of 45.9% in baseline LDL (P<.0001) between the alirocumab group and the placebo group. 
Weaknesses of the study include no evidence of subgroup analyses for race or gender. This study 
did not target the effectiveness of the drug on individuals with FH, yet the findings are still 
pertinent since individuals with FH often have been on maximally tolerated statin therapy. 
In a double blind study by Raal, et al.,  (2015) PCSK9 inhibitors focused on subjects 
(N=49) with HoFH. Of these, n=16 participants were administered a placebo and n=33 received 
the drug evolocumab, a PCSK9 inhibitor. All subjects were positive for HoFH and had been on 
lipid lowering therapy for at least 4 weeks (Raal et al., 2015). After 12 weeks of evolocumab 
administration a 30.9% reduction in serum LDL and 23% reduction in Apob resulted compared 
to the placebo group (P<0.0001) (Raal et al., 2015).  
 Lastly, in another study (N= 331) heterozygous subjects received PCSK9 therapy 
administered evolocumab either on a monthly basis (420 mg) or every 2 weeks (140 mg). Both 
groups had statistically significant reduction in serum LDL levels. Subjects receiving the 
monthly dose by the end of 12 weeks had a 61.3% reduction in serum LDL levels compared to 
the placebo group. This finding equates to a treatment difference of 59.2% (P<0.0001). Bi-
weekly doses of 140 mg led to a reduction in serum LDL of 59.2% compared to a placebo 
(P<0.0001) (Raal et al., 2015). 
Limitations of the research include the analysis of responses to therapy based on 
genotype was completed post-hoc rather than being pre-specified in the study methods or data 
collection plans.  Thus, this approach was used to determine the hypotheses and should not be 
viewed as findings. Also the study time frame was only 12 weeks, and for that reason durability 
of serum LDL reductions and safety could not be ascertained. 




 It is clear that the administration of PCSK9 inhibitors in both patients with or without FH 
can have significant serum LDL lowering results. In conditions that are of genetic nature, statins 
alone can be ineffective in lowering LDL concentrations and PCSK9 inhibitors can enhance 
statins in lipid lowering. This is especially important since statins alone can raise PCSK9 levels 
in individuals, subsequently FH, this approach exacerbatesin individuals with a PCSK9 gene 
mutation where PCSK9 proteins are already numerous in serum concentration. Also, in patients 
who do not tolerate statins, this therapy could aid in lowering LDL while titrating the statin dose 
downward.  This strategy could relieve patients of statin induced side effects from poor tolerance 
to the drug or high doses. 
APOB Inhibitors (mipomersen) 
 Mipomersen is an antisense agent that inhibits APOB synthesis and reduces the amount 
of APOB containing lipoproteins in circulation. When used in individuals with mild 
hypercholesterolemia or even homozygous FH this drug significantly reduced the concentration 
of circulating LDL and APOB. When combined with other lipid-lowering therapies it is even 
more effective (Stein et al., 2012). In a double-blind, placebo-controlled trial (N=114) subjects 
were administered mipomersen weekly at 200 mg resulted in a 28% decrease in LDL levels in 
HeFH individuals with CAD who could not achieve LDL control of <100mg/dl on maximum 
lipid-lowering therapy. Mipomersen is unique as it reduces LDL concentration at almost the 
same rate for both HeFH and HoFH individuals. Mipomersen lowered LDL by 25% in HoFH 
subjects and 28% in HeFH subects (Stein et al., 2012). The LDL lowering ability of mipomersen 
is similar across all LDL phenotypes and genotypes including HeFH, non-familial 
hypercholesterolemia and HoFH. Mipomersen was studied in addition to existing lipid-lowering 
statin therapy.  




 An adverse effect of APOB inhibitors is the accumulation of hepatic fat which can lead to 
hepatitis and liver damage. In this study a significant limitation occurred when 30% of subjects 
in both the placebo and mipomersen groups had unreadable magnetic resonance imaging (MRI) 
scans. MRI scans were utilized to observe hepatic fat content to determine whether mipomersen 
therapy should continue or cease. This technical and subject challenge had little effect on the 
study since there were still an adequate number of readable MRI scans to make a conclusion with 
and reach statistical significance (Stein et al., 2012). 
 In another study published by the European Heart Journal, mipomersen’s effects were 
studied over two years to evaluate the effectiveness and safety of long-term dosing in individuals 
with FH on maximally tolerated statin therapy. 142 patients were enrolled in the study (N=142) 
with HeFH (n=103) and HoFH (n=38) respectively who had successfully and recently completed 
a phase 3 mipomersen trial and did not have any adverse health conditions (clinically significant 
liver laboratory results, injection site reactions, flu-like symptoms) and did not  consume 
excessive amounts of alcohol  (Santos et al., 2013). Mipomersen was administered weekly at 200 
mg subcutaneously and a 2 week screening period and 24 week follow up succeeded the test 
where patients were assessed for drug efficacy and safety. Subject safety was monitored through 
assessment and laboratory findings every 4-7 weeks and ECGs were conducted to examine QT 
interval changes, a possible complication of mipomersen of which subjects were effected (n=2) 
(Santos et al., 2013). Laboratory results were monitored for hepatic damage to drug therapy 
(n=2), and other adverse effects (n=33). The most common adverse effect was noted to be 
injection site reactions (n=138). Elevated liver enzymes (a reversible condition was found with 
drug discontinuation) in the form of alanine aminotransferase were monitored and elevated in a 
small number of subjects (n=18) (Santos et al., 2013). 




 Effectiveness of mipomersen was noted by the 28-31% average reduction in APOB 
concentrations (Santos et al., 2013). Also noted was the small reduction in triglycerides and 
slight increase in HDL (P<0.01). Mean reduction in APOB by week 104 was 31% (P<0.001). 
Reduction of triglycerides, non HDL cholesterol and LDL was noted throughout the study with a 
17% decrease in LDL by week 104 (P<0.001) (Santos et al., 2013). 
 A serious limitation was the association of the authors to outside interests including 
pharmaceutical companies and research firms exposes a conflict of interest for this study. The 
authors either worked for or presented for pharmaceutical product developers. Another limitation 
was the source of funding by Genzyme, a subsidiary of the Sanofi Corporation who paid for the 
research and open publication of this study (Santos et al., 2013). 
MTP Inhibitors 
 The MTP inhibitor’s mechanism lies in its ability to inactivate MTP, a precursor in the 
construction of LDL and chylomicrons, both of which are lipoproteins. MTP inhibitors lower the 
amount of apoliprotein B containing lipoproteins which in turn lowers non-HDL cholesterol 
(Hewing et al., 2013). This study used rodents (mice) as subjects (N=24), to determine the 
effectiveness of MTP inhibitors in regressing atherosclerotic lesions. The researchers 
administered MTP inhibitors to the mice through dietary means in mice chow. MTP inhibitors 
greatly reduced circulating LDL. By the end of one week serum LDL levels were reduced by 
84% and by two weeks the level was reduced to by 94%. Atherosclerotic lesion size also were 
decreased, became less fatty and became more collagenous which is a sign of plaque 
stabilization in humans. Plaque size when comparing the MTP group against the control group 
there was a 39.4% decrease in size (p<0.001) (Hewing et al., 2013). The only significant 
limitation is this study was conducted on mice and not in humans: therefore findings may not be 




similar in human subjects. Along with a small sample (N=24) using mice is not clinically 
significant for humans. 
 Another study by researchers in the UK observed correlations between MTP inhibitor use 
and reduction of serum LDL (Kolovou, Vasiliadis, Gontoras, Kolovou, & Hatzigeorgiou, 2015). 
The case-study included two subjects (N=2) and found the results cannot be either statistically 
significant or clinically significant but the findings may be useful in developing future studies 
focusing on FH. Both subjects were homozygous for FH, had severely elevated LDL levels (both 
>300 mg/dL) and were required to undergo LDL-apherisis (a dialysis-like procedure that 
removes LDL from the blood). Researchers found that serum LDL cholesterol could be reduced 
by 40% when MTP inhibitors are combined with statin. LDL-apherisis was also impacted with 
frequency dramatically reduced. In one subject undergoing apheresis every other week, MTP 
inhibitors reduced need for the procedure to once every 10 to 12 weeks after 40 weeks of MTP 
inhibitor use. Another subject had reduced apheresis to once every 16-24 weeks (Kolovou, 
Vasiliadis, Gontoras, Kolovou, & Hatzigeorgiou, 2015). 
 Another MTP inhibitor lomitapide (Juxtapid) developed by pharmaceutical company 
Aegerion in conjunction with the University Of Pennsylvania School Of Medicine is reported to 
hold promise in HoFH individuals who have not responded to statins. In a phase 2 clincial trial, 
researchers investigated lomitapide and atorvastatin (statin drug) combination therapy and how it 
would compare to atorvastatin alone, the study (N=50) was conducted over 8 weeks. Researchers 
found that in combination, lomitapide and atorvastatin significantly lowered serum LDL levels 
than atorvastatin alone. The findings indicated Juxtapid reduces mean LDL levels 66% from 
baseline compared to placebo when in combination with atorvastatin; lomitipide alone decreases 
LDL by 35% from baseline (Aegerion Pharmaceuticals, 2011). 





 The serum LDL lowering effect of new classifications of Pharmacogenomic drugs is 
evident with treatment of FH.  More specifically, PCSK9 inhibitors, ApoB inhibitors and MTP 
inhibitors all were found to have better outcomes for individuals with FH either as an adjunct or 
replacement for traditional statin therapy. The variability of statins and the genetic factors that 
predispose an individual to statin intolerance resulted in a gap for successfully treating 
individuals with FH. Pharmacogenomics in some cases can be used as an adjunct to statin drugs 
to achieve lower target LDL levels in FH individuals who are on maximum tolerated statin 
therapy, or who do not tolerate statins. Pharmacogenomic therapies also have potential for 
tailoring treatments for individuals with non-familial dyslipidemias as the aforementioned 
pharmacotherapies have a substantial effect on serum LDL levels, ApoB, triglycerides and 
chylomicrons and, in some cases, weight reduction. 
Based on this review of only eight studies, the evidence suggests that genomic research 
advances with genetically based pharmacotherapies can lower serum LDL levels in individuals 
with a diagnosis of FH. However, additional studies are needed with larger sample sizes and 
more diverse subjects. More information is being discovered about genetic traits and FH and the 
role of precision medicine may have in managing symptoms and disease processes in individuals 
with this genetic trait. As the HGP continues to uncover genetic markers for other disease, more 
diagnostic and treatment options may become a reality for these conditions. While much remains 
unknown, the research evidence in this review suggests that the new pharmacogenomic medicine 
are effective in regulating the disease process of FH and hypercholesterolemia; thus, reducing 
long term health risks and other associated comorbidities specifically, PCSK9 Inhibitors, ApoB 
inhibitors and MTP inhibitors. 




Implications for Nursing 
 The next section highlights implications for nursing in respect to education, practice, 
policy and research followed by limitations of this integrated review of the literature focusing on 
the management of FH using pharmacogenomics.  
Education 
Given the mandate of the American Nurses Association and other professional nursing 
specialty organizations (Cheek, Bashore, & Brazeau, 2015; Greco, Tinley, & Seibert, 2011; 
Howington, Riddlesperger, Cheek, 2011), there is a need for nurse educators to integrate 
genomics into content curricula. This nursing mandate, coupled with President Obama’s 
Initiative on Precision Medicine reinforces an urgent need for a more robust understanding of 
human genomes, pharmacogenomics and precision medicine (Williams et al., 2016). More 
specifically, students must be informed about concepts related to human genetic traits in disease 
formation which is vital in developing, treating and evaluating nursing care plans in particular 
individuals who are at risk for or have been diagnosed with FH. As genetically based therapies 
become more specific to the genome of an individual it is ever more important that nurses 
understand precision therapie’s physiological processes (Cheek, Bashore, & Brazeau, 2015). 
Informed health professionals, specifically nurses, can be more effective at patient education and 
informing about genetic treatment principles. Not only is genetic related content important for 
students in pre-licensure nursing education programs, but continue education offerings must be 
mandatory for nurses who have been in the workforce for an extended period of time (Williams 
et al., 2016).  
Electronic resources are a source of current information that can augment nurses’ 
knowledge on genomics. For instance, the National Institute of Health Pharmacogenomics 




Research Network’s Clinical Pharmacogenetics Implementation Consortium (CPIC) (Caudle et 
al., 2014) provides information on current research relating to genetics and precision medication. 
This consortium, on a regular bases, releases peer-reviewed guidelines involving genetics and 
pharmacogenomics data is useful to improve treatment outcomes (Cheek, Bashore, & Brazeau, 
2015). The National Institute of Health’s Pharmacogenomics and Pharmacogenetics Knowledge 
Base (PharmGKB) (Thorn, Klein, & Altman, 2013), is another site that provides current 
evidence on pharmacogenomics that nurses in advanced practice, research and education can 
readily access (Cheek, Bashore, & Brazeau, 2015). 
Practice 
Clinicians must understand genetics concepts as these relate to disease processes and 
precision medicine for nursing assessments, care planning and outcomes evaluation. Core 
competencies related to genetics and pharmacogenomics have been identified and are important 
to enhance clinical reasoning and decision making (Williams et al., 2016).  In the roles of 
advocate, educator and counselor, nurses are expected to inform, assess, monitor and obtain 
signed consent from individuals who are considering genomic screening and pharmacogenomic 
treatment options. Nurses often educate individuals and family members about genetic tests; 
sometimes interpret results along with the physiology of genome traits and mutations that can 
lead to disease processes. The influence of genetic traits and the associated pharmacodynamics 
and pharmacokinetics that inform about drug transport and metabolization are even more 
important for advanced practice nurses to understand who are involved in prescribing and 
titrating medications that are genome dependent (Cheek, Bashore, & Brazeau, 2015). Another 
responsibility of nurse clinicians is administering and monitoring responses to pharmacogenomic 
interventions (Cheek, Bashore, & Brazeau, 2015). In the case of an individual diagnosed with 




FH, the nurse would monitor serum LDL levels and interpret pertinent laboratory values as well 
as monitor for side effects of the drug such as liver impairment.   
Policy 
 Stated objectives of the Whitehouse Initiative on Precision Medicine include accelerating 
biomedical research, providing health professionals with tools to treat genetic disease and 
incorporating researcher and evidence based medical interventions (Williams et al., 2016). This 
initiative at a societal level reinforces an urgent need for research on pharmacogenomics and 
appropriately treating genetic induced conditions. In turn, the evidence should be disseminated 
for use by clinicians to develop and implement precision interventions to treat and manage a 
particular genetic based condition such as FH (Cheek, Bashore, & Brazeau, 2015). Nurses are in 
a position to influence policy at national, state and local levels first by being informed; then, 
contacting and informing policy makers about genetic related initiatives. Another policy 
implication relates to reimbursement levels by third party payers for genetic screening and 
precision medicine. While pharmacogenomics may initially be deemed to be more costly by 3
rd
 
party payers, long term outcomes may be far more cost effective when applying 
pharmacogenomics and precision medicine. As advocates, nurses must have a greater presence 
on local, state and national advisory boards and other regulatory agencies in order to present the 
nursing perspective as well as advocating for consumers, specifically, in the area of genomics 
and FH.  
Research 
Based on a review of only eight articles for this thesis reinforces that limited research that 
has been published in the area of FH and precision medicine to treat this genetically based 
condition. There are multiple gaps in the literature. Studies are needed focusing on nursing 




topics, such as effective counseling approaches with individuals who are considering genetic 
screening. Evidence is needed on appropriate educational strategies focusing on 
pharmacogenomic interventions, managing associated side effects and supporting individuals 
that are recipients of precision medicine.  Additional research is needed that isolates FH 
phenotypes and measuring short and long term drug efficacy with theses genetic traits; as well as 
developing primary, secondary and tertiary prevention strategies. Since genomics and 
pharmacogenomics are a new medical frontier, studies are needed that focus on demographic 
diversity including gender, ethnic, racial and age factors to establish both statistical and clinical 
significance.  
Limitations 
 Several limitations are noted with this integrative review of the literature focusing on 
pharmacogenomics in FH. Associated with the inclusion criteria limiting publication time frame 
of five years 5 (2010-2015) that were written in the English language only eight articles were 
reviewed; seven of which had a very small sample size; and, one of which used rodents as 
subjects. The studies that were reviewed focused on select drugs and their effectiveness in 
treating individuals with persistent hypercholesterolemia, with minimal information on the drug 
effects on subgroups and side effects. There also was evidence of conflict of interests among the 
researchers and their financial sponsor (pharmaceutical companies) for the studies. 
Summary 
 The Human Genome Project has had far reaching applications for genomic technologies 
and pharmacogenomic interventions that are tailored to human conditions that are associated 
with genomic traits. Based on the integrative research literature review focusing on familial 
hypercholesterolemia, there is a paucity of articles on the topic. The research predominately is on 




emerging pharmacogenomic drugs and their effects on managing FH. This synthesis of eight 
research articles by this researcher summarizes that little is known on the topic along with 
extensive gaps in the evidence. Finally, implications for nursing education, practice, policy and 
research along with limitations are noted.    










































Limiters: English-language, peer reviewed, published between 2010-2015, included HMG-CoA 
reductase inhibitors (statins) as a comparison drug. 
  
Initial search terms “Pharmacogenomics” OR “Pharmacogenetics,” 
“genetics,” “genetic screening” and “nursing” using databases CINAHL, 
MEDLINE, PubMed and Cochrane. 
(n=18,312) 
 
Revised search shifted to include the terms “familial 
hypercholesterolemia” and drug class names 
“PCSK9 inhibitors”, “APOB Inhibitors” and “MTP 
inhibitors” 
Narrowed Search to include “PCSK9” 
(n=301) 
 
Studies included that met inclusion criteria 
(n=3) 
 
Studies Included that met inclusion criteria 
(n=2) 
 
Narrowed search to include “MTP Inhibitors” 
(n=31) 
 
Studies included that met inclusion criteria 
(n=3) 
Studies including familial 
hypercholesterolemia (FH) were given 
more consideration than those not 
including FH. Given the paucity of 
research studies looking at multiple 
forms of hypercholesterolemia were 
included. 
(n=8) 








Nine articles were included 
to give further relevance 
and background to this 
review. 
(n=9) 
Other scholarly relevant and pertinent sources from 
webpages that added to background 
(n=4) 










Table 3: Research Literature Reviewed 
 
Author  

















Lomitapide effective at 
lowering LDL in 
subjects with HoFH up 
to 66% 
Research supported by 
pharmaceutical company. Could 
be conflict of interest for 
researchers at University of 
Pennsylvania 
Stein, E. A., 
Dufour, R., Gagne, 
C., Gaudet, D., 
East, C., Donovan, 







ApoB inhibitors reduce 
LDL in heterozygous 
FH subjects by 28% 
from baseline when 
compared to a placebo 
(p<0.001) 
About 30% of MRIs not readable 
to determine hepatic fat content; 
medication side effect. 
Significance of hepatic fat and 
ALT level increases are uncertain. 
Hewing, B., 
Parathath, S., Mai, 
C. K., Fiel, M. I., 






MTP inhibitors reduce 
LDL & size of 
atherosclerotic lesions 
Study conducted on mice instead 
of humans. 
Santos, R. D., 
Duell, P. B., East, 
C., Guyton, J. R., 
Moriarty, P. M., 




N=142 Laboratory Safety and efficacy of 
mipomersen in subjects 
with FH. APOb 
reduction was 31% at 
104 weeks(P<0.001). 
Authors had associations with 
pharmaceutical companies. 
Funding came from a 
pharmaceutical company for 
research and publishing. 




Mittleman, R. S. HDL increased 
(P<0.01).  
Kereiakes, D. J., 
Robinson, J. G., 
Cannon, C. P., 
Lorenzato, C., 
Pordy, R., 
Chaudhari, U., & 




N=316 Laboratory PCSK9 inhibitors 
reduce LDL by 48% 
from baseline in 
subjects at high CV 
risk who were on 
maximally tolerated 
statins. 





Kolovou, V., & 
Hatzigeorgiou, G. 
2015 Case study  N=2 Laboratory MTP inhibitors reduce 
LDL by 40% in 
homozygous FH 
subjects on statin 
therapy. 
Very small sample size that isn’t 
statistically significant. 
Raal, F. J., 
Honarpour, N., 
Blom, D. J., 
Hovingh, G. K., Xu, 
F., Scott, R., . . . 




N=50 Laboratory PCSK9 inhibitors 
reduce LDL by 30.9% 




Short, 12 week study. Did not 
control for some subgroups. 
Raal, F. J., Stein, E. 
A., Dufour, R., 
Turner, T., Civeira, 





N=331 Laboratory PCSK9 inhibitors in 
heterozygous subjects 
reduce LDL by 60% 
when compared with 
placebo. 
Analysis of response to treatment 
based on genotype was not pre-
specified. Short duration of study, 
only12 weeks. 
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